BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28256712)

  • 1. Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.
    Moyal L; Yehezkel S; Gorovitz B; Keren A; Gilhar A; Lubin I; Sherman S; Hodak E
    Br J Dermatol; 2017 Sep; 177(3):791-800. PubMed ID: 28256712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
    Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
    PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells.
    Gluud M; Fredholm S; Blümel E; Willerslev-Olsen A; Buus TB; Nastasi C; Krejsgaard T; Bonefeld CM; Woetmann A; Iversen L; Litman T; Geisler C; Ødum N; Lindahl LM
    Dermatology; 2021; 237(2):277-282. PubMed ID: 32335549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
    Zhang C; Ni X; Konopleva M; Andreeff M; Duvic M
    J Invest Dermatol; 2004 Aug; 123(2):380-7. PubMed ID: 15245439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation.
    Rittig AH; Johansen C; Celis P; Odum N; Litman T; Woetmann A; Lindahl LM; Iversen L
    Exp Dermatol; 2021 Aug; 30(8):1141-1149. PubMed ID: 32492224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
    Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
    J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.
    Frei GM; Kremer M; Hanschmann KM; Krause S; Albeck M; Sredni B; Schnierle BS
    Br J Dermatol; 2008 Mar; 158(3):578-86. PubMed ID: 18241275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Moyal L; Arkin C; Gorovitz-Haris B; Querfeld C; Rosen S; Knaneh J; Amitay-Laish I; Prag-Naveh H; Jacob-Hirsch J; Hodak E
    Br J Dermatol; 2021 Nov; 185(5):999-1012. PubMed ID: 34053079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
    Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered microRNA expression in mycosis fungoides.
    Maj J; Jankowska-Konsur A; Sadakierska-Chudy A; Noga L; Reich A
    Br J Dermatol; 2012 Feb; 166(2):331-6. PubMed ID: 21966986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.
    You BR; Park WH
    Mol Carcinog; 2017 Dec; 56(12):2566-2577. PubMed ID: 28667779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.
    Garaicoa FH; Roisman A; Arias M; Trila C; Fridmanis M; Abeldaño A; Vanzulli S; Narbaitz M; Slavutsky I
    Tumour Biol; 2016 Oct; 37(10):13637-13647. PubMed ID: 27473081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
    Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered microRNA expression in folliculotropic and transformed mycosis fungoides.
    Marosvári D; Téglási V; Csala I; Marschalkó M; Bödör C; Timár B; Csomor J; Hársing J; Reiniger L
    Pathol Oncol Res; 2015 Jul; 21(3):821-5. PubMed ID: 25698383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
    Moyal L; Goldfeiz N; Gorovitz B; Rephaeli A; Tal E; Tarasenko N; Nudelman A; Ziv Y; Hodak E
    Invest New Drugs; 2018 Feb; 36(1):1-9. PubMed ID: 28884410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.